R&D | May 07, 2026
The company informed stock exchanges that the appellate authority has set aside the GST demand along with applicable interest and penalty
The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms
The company also announced a major portfolio shift, planning to divest its Immunodiagnostics business in China, a unit that generated approximately 6% of its fiscal 2025 revenue
The approval enables the company to directly sell health insurance plans to individuals and families while integrating its managed healthcare delivery model into retail offerings
More than 3,500 participants will join the nationwide AI-focused hackathon hosted as Indian Institute of Science
The company has also launched Elyara, a portfolio of products in regenerative medical aesthetics focused on non-invasive skin and hair restoration
The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients
FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
The US FDA completed a pre-license inspection of Biocon Biologics’ biosimilars manufacturing site at Biocon Park between April 20 and April 29, 2026
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
